Skip to main content
Top
Published in: Familial Cancer 3/2014

01-09-2014 | Original Article

Analysis of patient reports on the referral process to two NSW cancer genetic services

Authors: Grace I. Butel-Simoes, Allan D. Spigelman

Published in: Familial Cancer | Issue 3/2014

Login to get access

Abstract

To evaluate trends and associations surrounding patient referral to cancer genetics services in NSW. The specific aims of the questionnaire used to collect information were to: (1) quantify the types of cancers being referred, (2) identify the source of referral for the patients, (3) categorise the referral as being either sought by the patient or suggested by the doctor, (4) quantify how often family history was asked, (5) determine who first raised the topic of family history, (6) identify any discouragement faced by patients, (7) clarify the cancer status of patients referred. A comparative patient-reported study was carried out using a questionnaire as the data collection tool in structured short interviews. The questions were aimed at eliciting the patient’s understanding of why they were referred to the clinic, whether family history was discussed at the time of referral and who raised the issue via a series of YES/NO and open response questions. Data were collected from March 2012 to August 2012 from two different clinics, St Vincent’s Hereditary Cancer Clinic, Sydney and the Hunter Family Cancer Service, Newcastle—both in New South Wales, Australia. Written consent was obtained. The study found that specialists were responsible for the majority of the 150 referrals and were more likely to be proactive in referring, as opposed to GPs (Phi and Cramer’s V test). Patients reported that at the time of referral their family history was not asked in 13.5 % of cases, despite being significant. In the 131 cases where family history was discussed, it was the patient on approximately 2 in 5 occasions that brought up the topic. The most common types of cancer seen were breast cancer and colorectal. At both services GP referrals were more common then specialist referrals. On three occasions patients sought referral after being notified that the bloods they had collected by their GP for genetic testing were held by the laboratory due to failure to follow protocol. Six patients reported being discouraged to attend when seeking a referral. At the time of referral 58.7 % of patients were considered to be without cancer. Overall, 20 % of patients requested their referral to the cancer genetics clinics. The discussion of family history in the context of familial cancer is key to accurate risk assessment and management advice. Further education of doctors is required as evidenced by the number of patients where family history was not asked and in those patients who had bloods collected by their GP without counselling.
Appendix
Available only for authorised users
Literature
1.
go back to reference Julian-Reynier C, Eisinger F, Chabal F, Aurran Y, Bignon Y-J, Noguès C, Machelard M, Maugard C, Vennin P, Sobol H (1998) Cancer genetic clinics: why do women who already have cancer attend? Eur J Cancer 34(10):1549–1553PubMedCrossRef Julian-Reynier C, Eisinger F, Chabal F, Aurran Y, Bignon Y-J, Noguès C, Machelard M, Maugard C, Vennin P, Sobol H (1998) Cancer genetic clinics: why do women who already have cancer attend? Eur J Cancer 34(10):1549–1553PubMedCrossRef
2.
go back to reference Bleiker EMA, Hahn DEE, Aaronson NK (2003) Psychosocial issues in cancer genetics. Acta Oncol 42(4):276–286PubMedCrossRef Bleiker EMA, Hahn DEE, Aaronson NK (2003) Psychosocial issues in cancer genetics. Acta Oncol 42(4):276–286PubMedCrossRef
4.
go back to reference Miller FA, Carroll JC, Wilson BJ, Bytautas JP, Allanson J, Cappelli M, de Laat S, Saibil F (2010) The primary care physician role in cancer genetics: a qualitative study of patient experience. Fam Pract 27(5):563–569PubMedCrossRef Miller FA, Carroll JC, Wilson BJ, Bytautas JP, Allanson J, Cappelli M, de Laat S, Saibil F (2010) The primary care physician role in cancer genetics: a qualitative study of patient experience. Fam Pract 27(5):563–569PubMedCrossRef
5.
6.
go back to reference de Bock GH, Asperen CJV, de Vries JM, Hageman GCHA, Springer MP, Kievit J (2001) How women with a family history of breast cancer and their general practitioners act on genetic advice in general practice: prospective longitudinal study. Br Med J 322:26–27CrossRef de Bock GH, Asperen CJV, de Vries JM, Hageman GCHA, Springer MP, Kievit J (2001) How women with a family history of breast cancer and their general practitioners act on genetic advice in general practice: prospective longitudinal study. Br Med J 322:26–27CrossRef
7.
go back to reference Prochniak CF, Martin LJ, Miller EM, Knapke SC (2012) Barriers to and motivation for physician referral of patients to cancer genetics clinics. J Genet Couns 21:305–325PubMedCrossRef Prochniak CF, Martin LJ, Miller EM, Knapke SC (2012) Barriers to and motivation for physician referral of patients to cancer genetics clinics. J Genet Couns 21:305–325PubMedCrossRef
8.
go back to reference Kohut K, D’Mello L, Bancroft EK, Thomas S, Young M-A, Myhill K et al (2012) Implications for cancer genetics practice of pro-actively assessing family history in a general practice cohort in North West London. Fam Cancer 11:107–113PubMedCrossRef Kohut K, D’Mello L, Bancroft EK, Thomas S, Young M-A, Myhill K et al (2012) Implications for cancer genetics practice of pro-actively assessing family history in a general practice cohort in North West London. Fam Cancer 11:107–113PubMedCrossRef
9.
go back to reference Womens Concerns Study Group (2001) Raising concerns about family history of breast cancer in primary care consultations: prospective, population based study. Br Med J 322:27–28CrossRef Womens Concerns Study Group (2001) Raising concerns about family history of breast cancer in primary care consultations: prospective, population based study. Br Med J 322:27–28CrossRef
10.
go back to reference Trivers KF, Baldwin L-M, Miller JW, Matthews B, Andrilla CHA, Lishner DM, Goff BA (2011) Reported referral for genetic counselling or BRCA1/2 testing among United States physicians. Cancer 117(23):5334–5343PubMedCrossRef Trivers KF, Baldwin L-M, Miller JW, Matthews B, Andrilla CHA, Lishner DM, Goff BA (2011) Reported referral for genetic counselling or BRCA1/2 testing among United States physicians. Cancer 117(23):5334–5343PubMedCrossRef
11.
go back to reference Wideroff L, Freedman AN, Olson L, Klabunde CN, Davis W, Srinath KP, Ballard-Barbash R (2003) Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomark Prev 12:295–303 Wideroff L, Freedman AN, Olson L, Klabunde CN, Davis W, Srinath KP, Ballard-Barbash R (2003) Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomark Prev 12:295–303
13.
go back to reference Yoon P, Scheuner M, Peterson-Oehlke K, Gwinn M, Faucett A, Khoury M (2002) Can family history be used as a tool for public health and preventive medicine? Genet Med 4:304–310PubMedCrossRef Yoon P, Scheuner M, Peterson-Oehlke K, Gwinn M, Faucett A, Khoury M (2002) Can family history be used as a tool for public health and preventive medicine? Genet Med 4:304–310PubMedCrossRef
14.
go back to reference Stratton M (2011) Exploring the genomes of cancer cells: progress and promise. Science 331(6024):1553–1558PubMedCrossRef Stratton M (2011) Exploring the genomes of cancer cells: progress and promise. Science 331(6024):1553–1558PubMedCrossRef
15.
go back to reference Rolnick S, Rahm A, Jackson J, Nekhlyudov L, Goddard K (2011) Barriers in identification and referral to genetic counselling for familial cancer risk: the perspective of genetic service providers. J Genet Couns 20(3):314–322PubMedCrossRef Rolnick S, Rahm A, Jackson J, Nekhlyudov L, Goddard K (2011) Barriers in identification and referral to genetic counselling for familial cancer risk: the perspective of genetic service providers. J Genet Couns 20(3):314–322PubMedCrossRef
Metadata
Title
Analysis of patient reports on the referral process to two NSW cancer genetic services
Authors
Grace I. Butel-Simoes
Allan D. Spigelman
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2014
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-014-9710-y

Other articles of this Issue 3/2014

Familial Cancer 3/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine